Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,478,052 | 8,293,305 | 7,497,020 | 4,565,081 | 2,231,834 |
| Depreciation Amortization | 623,893 | 3,051,472 | 3,666,288 | 2,647,159 | 1,036,568 |
| Accounts receivable | N/A | -808,363 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | 172,750 | N/A | N/A | N/A |
| Other Working Capital | -1,389,272 | -2,508,167 | -3,112,301 | -2,429,457 | -1,763,300 |
| Other Operating Activity | -175,175 | 2,007,063 | -687,429 | -454,103 | -62,975 |
| Operating Cash Flow | $1,537,498 | $10,208,060 | $7,363,578 | $4,328,680 | $1,442,127 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 8,085 | 142,420 | 14,827 | N/A | -27,709 |
| PPE Investments | -261,415 | -1,745,959 | -1,029,796 | -611,705 | -260,717 |
| Net Acquisitions | -1,561,752 | -2,266,845 | -2,268,516 | -1,107,212 | -1,008,859 |
| Purchase Of Investment | N/A | N/A | -70,091 | -60,102 | N/A |
| Sale Of Investment | N/A | N/A | 186,010 | 24,041 | N/A |
| Purchase Sale Intangibles | -215,600 | -2,007,061 | -1,446,297 | -722,560 | -206,558 |
| Other Investing Activity | -160,353 | -1,711,673 | -1,280,504 | -607,699 | -143,584 |
| Investing Cash Flow | $-1,975,435 | $-5,582,057 | $-4,448,070 | $-2,362,677 | $-1,440,868 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 1,611,610 | 1,430,790 | 742,693 | 136,231 | 74,311 |
| Debt Issued | N/A | 2,609,707 | 2,667,494 | 2,648,495 | 2,541,671 |
| Debt Repayment | N/A | -1,846,180 | -1,889,756 | -1,881,860 | N/A |
| Common Stock Issued | 10,780 | 19,781 | 18,871 | 18,698 | 15,114 |
| Common Stock Repurchased | -439,285 | -1,815,850 | -1,516,387 | -1,079,165 | -311,097 |
| Dividend Paid | -866,443 | -3,381,147 | -2,585,272 | -1,693,541 | -770,814 |
| Other Financing Activity | 49,858 | -1,876,511 | -1,250,852 | -170,957 | -468,534 |
| Financing Cash Flow | $366,520 | $-4,859,410 | $-3,813,209 | $-2,022,098 | $1,080,651 |
| Exchange Rate Effect | 2,695 | -25,055 | 29,654 | -49,417 | -13,855 |
| Beginning Cash Position | 4,379,375 | 4,487,536 | 4,586,904 | 4,545,047 | 4,286,079 |
| End Cash Position | 4,310,652 | 4,229,071 | 3,718,856 | 4,439,534 | 5,354,134 |
| Net Cash Flow | $-68,723 | $-258,465 | $-868,048 | $-105,512 | $1,068,056 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,537,498 | 10,208,060 | 7,363,578 | 4,328,680 | 1,442,127 |
| Capital Expenditure | -297,798 | -1,777,608 | -1,044,623 | -619,718 | -261,976 |
| Free Cash Flow | 1,239,701 | 8,430,452 | 6,318,955 | 3,708,962 | 1,180,151 |